Investigational drug · Phase 3
HLX13
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatocellular Carcinoma (HCC).
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "HLX13"
First trial start
2025
Apr 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HLX13", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma (HCC)
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HLX13" as an intervention, largest first.
- A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular CarcinomaPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT06841185 · 656 participants (planned) · Start Apr 30, 2025 · Primary completion Jun 6, 2027
Drug: HLX13; US-sourced YERVOY® and 1 more · For: Hepatocellular Carcinoma (HCC)
- A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male SubjectsPivotal-lookingStatus unknown
Shanghai Henlius BiotechIndustry
NCT06159101 · 304 participants (planned) · Start Nov 28, 2023 · Primary completion May 28, 2024
Drug: HLX13; CN-sourced ipilimumab and 2 more · For: Healthy Male Volunteers
Sites: Anhui, China
Shanghai Henlius BiotechIndustry
NCT07176650 · 246 participants (planned) · Start Nov 25, 2025 · Primary completion Dec 2026
Drug: HLX13; Yervoy and 1 more · For: Hepatocellular Carcinoma (HCC)
Sites: Glendale, California; Jacksonville, Florida; Margate, Florida · 51 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hepatocellular Carcinoma (HCC)
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- CobolimabPhase 32 trials
GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma
- IBI310Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma
- TPST-1120Phase 32 trials
Roche (Genentech) · Advanced Liver Cancers, Hepatocellular Carcinoma (HCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.